PT - JOURNAL ARTICLE AU - Luchsinger, Larry L. AU - Ransegnola, Brett AU - Jin, Daniel AU - Muecksch, Frauke AU - Weisblum, Yiska AU - Bao, Weili AU - George, Parakkal Jovvian AU - Rodriguez, Marilis AU - Tricoche, Nancy AU - Schmidt, Fabian AU - Gao, Chengjie AU - Jawahar, Shabnam AU - Pal, Mouli AU - Schnall, Emily AU - Zhang, Huan AU - Strauss, Donna AU - Yazdanbakhsh, Karina AU - Hillyer, Christopher D. AU - Bieniasz, Paul D. AU - Hatziioannou, Theodora TI - Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients AID - 10.1101/2020.06.08.20124792 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.08.20124792 4099 - http://medrxiv.org/content/early/2020/09/09/2020.06.08.20124792.short 4100 - http://medrxiv.org/content/early/2020/09/09/2020.06.08.20124792.full AB - The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being employed to determine seroprevalence in populations to select convalescent plasmas for therapeutic trials, and to guide policies about reopening. However, tests have substantial variability in sensitivity and specificity, and their ability to quantitatively predict levels of nAb is unknown. We collected 370 unique donors enrolled in the New York Blood Center Convalescent Plasma Program between April and May of 2020. We measured levels of antibodies in convalescent plasma using commercially available SARS-CoV-2 detection tests and in-house ELISA assays and correlated serological measurements with nAb activity measured using pseudotyped virus particles, which offer the most informative assessment of antiviral activity of patient sera against viral infection. Our data show that a large proportion of convalescent plasma samples have modest antibody levels and that commercially available tests have varying degrees of accuracy in predicting nAb activity. We found the Ortho Anti-SARS-CoV-2 Total Ig and IgG high throughput serological assays (HTSAs), as well as the Abbott SARS-CoV-2 IgG assay, quantify levels of antibodies that strongly correlate with nAb assays and are consistent with gold-standard ELISA assay results. These findings provide immediate clinical relevance to serology results that can be equated to nAb activity and could serve as a valuable ‘roadmap’ to guide the choice and interpretation of serological tests for SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding source for TH, PBD, FM, YW and FS were NIH R01AI78788 and R37AI064003. Funding sources did not have a role in the writing of the manuscript or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New York Blood Center IRB has determined this project does not meet the definition of human subject research under the purview of the IRB according to federal regulations. IRB Reference ID: 1596981-1 IRB Reference Title: COVID19 Convalescent Plasma Serology TestingAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be made available upon request.